国际动态存档 （2015年7月3期）
- Gilead Won't Run Out of Hep C Patients, or Dollars, Anytime Soon
- Suit says CVS manipulated generic drug prices
- Brilinta? Brintellix? FDA warns of drug name mix-ups
- Sales of MannKind's inhaled insulin continue slow start
- CVS And IBM's Watson Cloud Pursue Ways To Predict Patient Health
- Roche's Perjeta gets new EU indication
- Juno Announces FDA Clearance of Investigational New Drug Application for JCAR015 in Adult Relapsed/Refractory Acute Lymphoblastic Leukemia
- Amgen profit tops Street view, boosts full-year forecast
- “Sharp” Rise in Rx Spending In 2014 Makes Headlines; Will “Subside Somewhat” In 2015
- Why Pharma Must Change Its Model
- Former Teva Employee Blames Firing on Helping Feds With Bribery Probe
- AstraZeneca tops Q2 estimates on strength of diabetes drugs and clot-buster Brilinta
- FDA Approves Deltoid Injection Site for Abilify Maintena (aripiprazole) for extended-release injectable suspension in the Treatment of Schizophrenia
- Researchers develop mobiLab smartphone DNA test for chlamydia
- Eyeing big returns, drugmakers ready new hepatitis-C drug launches
- LixiLan Combines Lantus and Lyxumia; Combo Beats Either Alone
- Express Scripts says costly new cholesterol drugs could 'wreak havoc'
- The Top Drug Launches Of All Time
- Serious Risks About Existing Drugs Aren’t Given to Trial Participants
- A small molecule 'exercise mimetic' may help control Type 2 diabetes and obesity
- NICE recommends three new treatment options for hepatitis C in draft guidance
- Strong Sales of Sovaldi/Harvoni Set New Record
- By 2024, health spending will be nearly a fifth of the economy
- Many Concerned About Safety, True Value of Sequencing Tests
- GlaxoSmithKline Q2 beats despite Advair hit, lower margins
- Gores Group said to mull sale of immunotherapy business Therakos
- FDA approves non-surgical temporary balloon device to treat obesity
- Therapeutic Focus: Oncology
- Four challenges we have to crack before immune therapy can revolutionize how we fight cancer
- Has Mylan Labs Been Stichting it to Shareholders? A Lawsuit Says ‘Yes!’
- Hard-hit Biogen needs to act fast, analysts say--or beware its deal-hungry peers
- Sanofi to Join Regeneron in Quest to Unleash Immune System on Cancer
- Regeneron's George Yancopoulos Becomes Pharma's First Billionaire R&D Chief
- Merck Enhances Immuno-Oncology Portfolio with Acquisition of cCAM Biotherapeutics
- UPDATE 1-Merck raises forecast on strong sales of diabetes, cancer drugs
- 路人丙: 新药发现的低悬果实
- Pipi_WHU: 新药发现的低悬果实
- 路人丙: Galapagos放弃IPF资产、吉利德空手而归
- Tan, Chengfang: Galapagos放弃IPF资产、吉利德空手而归
- 配体效率遭到质疑 | 美中药源: 你笑我无知类药性本不存在？
- Songdanqing: 你笑我无知类药性本不存在？
- 路人丙: 中国新药的新时代
- 康, 荣明: 中国新药的新时代
合作伙伴
微信号：美中药源